Home » Stocks » MYOV

Myovant Sciences Ltd. (MYOV)

Stock Price: $20.54 USD -0.92 (-4.29%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 1.86B
Revenue (ttm) 33.33M
Net Income (ttm) -250.44M
Shares Out 89.74M
EPS (ttm) -2.81
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $20.54
Previous Close $21.46
Change ($) -0.92
Change (%) -4.29%
Day's Open 21.50
Day's Range 20.51 - 21.70
Day's Volume 801,986
52-Week Range 6.55 - 27.62

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
24/7 Wall Street - 1 week ago

Over halfway through the trading day on Wednesday, and the broad markets are making a run into the afternoon.

Other stocks mentioned: TSLA, AMRS, C, GS, JPM, KDP, MDB, MS, Z, ZG
GlobeNewsWire - 1 week ago

BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Myovant Sciences (NYSE: MYOV), please note that in the first paragraph of the...

GlobeNewsWire - 1 week ago

BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, ch...

GlobeNewsWire - 1 week ago

BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that ORGOVYX™ (relug...

GlobeNewsWire - 1 week ago

NEW YORK and LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Sumitovant Biopharma Ltd., the majority shareholder of Myovant Sciences (NYSE: MYOV),  announced today that Myovant Sciences, a healthcar...

GlobeNewsWire - 1 week ago

BASEL, Switzerland, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of D...

Zacks Investment Research - 2 weeks ago

Myovant Sciences (MYOV) and Pfizer enter collaboration agreement to develop and commercialize relugolix monotherapy and combination regimen for prostate cancer and uterine fibroids, respectively.

Other stocks mentioned: PFE
Benzinga - 2 weeks ago

Osmotica Pharmaceuticals (NASDAQ: OSMT) shares were trading higher Monday in anticipation of a ruling by the FDA on the company's New Drug Application for Arbaclofen ER in patients with multip...

Other stocks mentioned: AYTU, KNTE, OSMT
Business Insider - 2 weeks ago

Shares of Myovant surged as much as 35% to $30 on Monday after the biopharmaceutical company announced a partnership with Pfizer to develop and commercialize a drug for the treatment of prosta...

Other stocks mentioned: PFE
Market Watch - 2 weeks ago

Shares of Myovant Sciences soared 27% Monday, after its parent Sumitovant Biopharma unveiled an agreement with Pfizer Inc. to jointly develop a treatment for prostate cancer and women's health...

Other stocks mentioned: PFE
The Motley Fool - 2 weeks ago

Investors are cheering a big collaboration with Pfizer.

24/7 Wall Street - 2 weeks ago

Myovant Sciences Ltd. (NYSE: MYOV) shares shot up on Monday after the company announced a new collaboration with the pharmaceutical giant Pfizer Inc.

Other stocks mentioned: PFE
Benzinga - 2 weeks ago

Myovant Sciences Ltd (NYSE: MYOV) stock is adding about one-fourth of its market capitalization Monday following a licensing deal with Pfizer Inc. (NYSE: PFE). What Happened: Myovant announced...

Other stocks mentioned: PFE
Schaeffers Research - 2 weeks ago

The shares of Myovant Sciences Ltd (NYSE:MYOV) are up 27.2% at $29.08 at last check, gapping to record highs, after the biopharmaceutical concern announced a collaboration with Pfizer (PFE) to...

Other stocks mentioned: PFE
GlobeNewsWire - 2 weeks ago

Myovant and Pfizer to jointly develop and commercialize ORGOVYX™ (relugolix) and relugolix combination tablet and share profits and expenses in the U.S. and Canada

Other stocks mentioned: PFE
Market Watch - 2 weeks ago

Shares of Myovant Sciences soared 16% in premarket trade Monday, after its parent Sumitovant Biopharma said Myovant will work with Pfizer Inc. to jointly develop a treatment for men's and wome...

Other stocks mentioned: PFE
GlobeNewsWire - 2 weeks ago

Myovant and Pfizer to jointly develop and commercialize ORGOVYXTM (relugolix) and relugolix combination tablet and share profits and expenses in the U.S. and CanadaMyovant to receive an upfron...

Other stocks mentioned: PFE
GlobeNewsWire - 2 weeks ago

BASEL, Switzerland and NEW YORK, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced a collaboration to develop and commercialize relugo...

Seeking Alpha - 3 weeks ago

Riding strong data, Myovant recently secured FDA approval for relugolix in treating advanced prostate cancer. Under the brand Orgovyx, Myovant will market the said drug as soon as in January.

GlobeNewsWire - 4 weeks ago

•ORGOVYX is the first approved therapy in the Sumitovant Biopharma family of companies •ORGOVYX is the first approved therapy in the Sumitovant Biopharma family of companies

GlobeNewsWire - 4 weeks ago

BASEL, Switzerland, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that the U.S. Food a...

Zacks Investment Research - 1 month ago

Investors need to pay close attention to Myovant Sciences (MYOV) stock based on the movements in the options market lately.

GlobeNewsWire - 1 month ago

BASEL, Switzerland, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, invites investors and the general pu...

GlobeNewsWire - 2 months ago

BASEL, Switzerland, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it approved equ...

Seeking Alpha - 2 months ago

Myovant Sciences' (MYOV) CEO Lynn Seely on Q2 2020 Results - Earnings Call Transcript

Benzinga - 2 months ago

Shares of Myovant Sciences (NYSE:MYOV) rose 0.2% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 5.06% over the past year to ($0.75), whi...

GlobeNewsWire - 2 months ago

BASEL, Switzerland, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced corporate updates an...

Seeking Alpha - 2 months ago

As you know, Myovant's shares recently tumbled due to ambiguous Phase 3 data release for its prostate cancer franchise. Upon closer inspection, I believe that relugolix will ultimately be FDA-...

Seeking Alpha - 2 months ago

Myovant has positive Phase 3 results in all 3 indications for its main drug relugolix. The stock has taken a huge dive based on disappointing results on a secondary endpoint of the relugolix P...

GlobeNewsWire - 2 months ago

BASEL, Switzerland, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webca...

GlobeNewsWire - 2 months ago

BASEL, Switzerland, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the presentation of ...

Seeking Alpha - 3 months ago

Myovant: Relugolix Has Strong Competition

GlobeNewsWire - 3 months ago

BASEL, Switzerland, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of R...

Investors Business Daily - 3 months ago

Myovant Sciences posted poor trial data for part of a Phase 3 study for a prostate cancer treatment that awaits key FDA action later this year, and MYOV stock plummeted out of a buy zone. The ...

Newsfile Corp - 3 months ago

Atlanta, Georgia--(Newsfile Corp. - September 29, 2020) - Holzer & Holzer, LLC is investigating whether Myovant Sciences Ltd. (NYSE: MYOV) ("Myovant" or the "Company") complied with federal ...

GlobeNewsWire - 3 months ago

BASEL, Switzerland, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced results of an add...

Zacks Investment Research - 3 months ago

Investors need to pay close attention to Myovant Sciences (MYOV) stock based on the movements in the options market lately.

GlobeNewsWire - 3 months ago

BASEL, Switzerland, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the launch of its...

InvestorPlace - 3 months ago

The pandemic has raised awareness about the value of biotech across the world. In turn, these biotech stocks will benefit down the road.

Other stocks mentioned: ADAP, CCXI, KOD, MCRB, NVAX, SRNE
Seeking Alpha - 3 months ago

Myovant Reports Data, And Other News: The Good, Bad And Ugly Of Biopharma

GlobeNewsWire - 4 months ago

BASEL, Switzerland, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the presentation ...

GlobeNewsWire - 5 months ago

BASEL, Switzerland, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that its New Drug ...

GlobeNewsWire - 5 months ago

BASEL, Switzerland, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced corporate updates ...

Seeking Alpha - 5 months ago

Myovant Sciences Has Limited Downside At Its Current Price

GlobeNewsWire - 6 months ago

BASEL, Switzerland, July 06, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the presentation o...

GlobeNewsWire - 6 months ago

CHICAGO, Ill.; SAN MATEO, Calif.; LOS ANGELES, Calif.; and BASEL, Switzerland, June 30, 2020 (GLOBE NEWSWIRE) -- BlackDoctor.org, Evidation Health, Movember, and Myovant Sciences (NYSE: MYOV...

Zacks Investment Research - 6 months ago

Myovant (MYOV) reports positive top-line data from the phase III study on the relugolix combination therapy in women suffering from pain associated with endometriosis.

Investors Business Daily - 6 months ago

Shares of Myovant popped to a six-month high Tuesday after the biotech's endometriosis treatment succeeded in a Phase 3 test. This puts Myovant up against Neurocrine and AbbVie.

Market Watch - 6 months ago

Shares of Myovant Sciences Ltd. MYOV, +4.43% gained 7% in premarket trading on Tuesday after the drugmaker said a late-stage clinical trial for its experimental endometriosis drug hit its prim...

GlobeNewsWire - 6 months ago

BASEL, Switzerland, June 23, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced top-line results f...

About MYOV

Myovant Sciences, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as pa... [Read more...]

Industry
Biotechnology
IPO Date
Oct 27, 2016
Stock Exchange
NYSE
Ticker Symbol
MYOV
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for MYOV stock is "Buy." The 12-month stock price forecast is 36.14, which is an increase of 75.95% from the latest price.

Price Target
$36.14
(75.95% upside)
Analyst Consensus: Buy